Institutional members access full text with Ovid®

Share this article on:

Outcomes and Prognostic Factors for Squamous-Cell Carcinoma of the Anal Canal: Analysis of Patients From the National Cancer Data Base.

Bilimoria, Karl Y. M.D., M.S.1,2; Bentrem, David J. M.D.1; Rock, Colin E. B.S.1; Stewart, Andrew K. M.A.2; Ko, Clifford Y. M.D., M.S., M.S.H.S.2,3; Halverson, Amy M.D.1

Diseases of the Colon & Rectum: April 2009 - Volume 52 - Issue 4 - pp 624-631
doi: 10.1007/DCR.0b013e31819eb7f0
Original Contributions

PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.

METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000). Univariate and multivariable methods were used to assess factors associated with survival. Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.

RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent). Overall five-year survival was 58.0 percent. The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663). On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, ≥65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001). There was not a significant difference in survival by hospital type or year of diagnosis.

CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.

1 Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

2 Cancer Programs, American College of Surgeons, Chicago, Illinois

3 Department of Surgery, University of California, Los Angeles, and Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, California

Dr. Bilimoria is supported by the American College of Surgeons Clinical Scholars in Residence program.

Address of correspondence: Karl Y. Bilimoria, M.D., M.S., American College of Surgeons, Cancer Programs, 633 North Saint Clair Street, 25th Floor, Chicago, Illinois 60611. E-mail: k-bilimori@northwestern.edu

© The ASCRS 2009